Comparative genome- and proteome analysis of cerebral cortex from MK-801 treated rats

Journal of Neuroscience Research

Volumn 71, Issue 4, 2003, Pages 526-533

  Paulson, Linda ^a,c   Martin, Peter ^b   Persson, Anders ^a   Nilsson, Carol L ^a   Ljung, Elisabeth ^b   Westman Brinkmalm, Ann ^a   Eriksson, Peter S ^a   Blennow, Kaj ^a   Davidsson, Pia ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Carlsson Research AB   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Brain; cDNA microarray; MK 801; Rat; Two dimensional gel electrophoresis

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; BETA ACTIN; CASEIN KINASE II; CREATINE KINASE; CYTOCHROME C OXIDASE; DIZOCILPINE; DNA; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTAMATE DECARBOXYLASE; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 72; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEURON SPECIFIC ENOLASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN C JUN; PROTEOLIPID PROTEIN; PROTEOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE DEHYDROGENASE; RIBOSOME PROTEIN; STATHMIN; SUPEROXIDE DISMUTASE; SYNAPTOTAGMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; GENE CONTROL; GENOME ANALYSIS; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTO ONCOGENE; RAT; SCHIZOPHRENIA; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANIMALS; CEREBRAL CORTEX; DIZOCILPINE MALEATE; GENE EXPRESSION REGULATION; GENOME; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOME; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0037441519     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10509     Document Type: Article

References (42)

1. Aksenova MV, Burbaeva GS, Kandror KV, Kapkov DV, Stepanov AS. 1991. The decreased level of casein kinase 2 in brain cortex of schizophrenic and Alzheimer's disease patients. FEBS Lett 279:55-57.
2. Ban TA, Guy W, Wilson WH. 1984. Pharmacotherapy of chronic hospitalized schizophrenics: diagnosis and treatment. Psychiatr J Univ Ott 9:191-195.
3. Blackstock WP, Weir MP. 1999. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17:121-127.
4. Blennow K, Bogdanovic N, Gottfries CG, Davidsson P. 1999. The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia. J Mol Neurosci 13:101-109.
5. Carlsson A, Lindqvist M. 1973. Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25:437-440.
6. carlsson M, Carlsson A. 1990. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
7. Cassimeris L. 2002. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 14:18-24.
8. Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C. 2001. Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 8:723-742.
9. Davidsson P, Gottfries J, Bogdanovic N, Ekman R, Karlsson I, Gottfries CG, Blennow K. 1999. The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains. Schizophr Res 40:23-29.
10. Edgar PF, Schonberger SJ, Dean B, Faull RL, Kydd R, Cooper GJ. 1999. A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Mol Psychiatry 4:173-178.
11. Ellison G. 1995. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 20:250-267.
12. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E, DiGiorgi Gerevini V. 2000. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57:1061-1069.
13. Hazlett EA, Buchsbaum MS, Haznedar MM, Singer MB, Germans MK, Schnur DB, Jimenez EA, Buchsbaum BR, Troyer BT. 1998. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 35:186-198.
14. Hiramatsu M, Cho AK, Nabeshima T. 1989. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166:359-366.
15. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia [see comments]. Am J Psychiatry 148:1301-1308.
16. Javitt DCZ 1991. Mechanisms of phencyclidine (PCP)-N-aspartate receptor interaction: implications for schizophrenia. Schizophrenia Res Prog 12-19.
17. Juhaszova M, Church P, Blaustein MP, Stanley EF. 2000. Location of calcium transporters at presynaptic terminals. Eur J Neurosci 12:839-846.
18. Klushnik TP, Spunde A, Yakovlev AG, Khuchua ZA, Saks VA, Vartanyan ME. 1991. Intracellular alterations of the creatine kinase isoforms in brains of schizophrenic patients. Mol Chem Neuropathol 15:271-280.
19. Linden AM, Vasanen J, Storvik M, Lakso M, Korpi ER, Wong G, Castren E. 2001. Uncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptors alter the mRNA expression of proteins associated with the NMDA receptor complex. Pharmacol Toxicol 88:98-105.
20. Marchbanks RM, Mulcrone J, Whatley SA. 1995. Aspects of oxidative metabolism in schizophrenia. Br J Psychiatry 167:293-298.
21. Maurer I, Zierz S, Moller H. 2001. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 48:125-136.
22. Mazeh D, Sirota P, Patya M, Novogrodsky A. 1998. Antibodies to neuroblastoma cell line proteins in patients with schizophrenia. J Neuroimmunol 84:218-222.
23. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. 2000. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28:53-67.
24. Pollard TD. 1990. Actin. Curr Opin Cell Biol 2:33-40.
25. Popot JL, Pham Dinh D, Dautigny A. 1991. Major Myelin proteolipid: the 4-alpha-helix topology. J Membr Biol 120:233-246.
26. Pradet-Balade B, Boulme F, Beug H, Mullner EW, Garcia-Sanz JA. 2001. Translation control: bridging the gap between genomics and proteomics? Trends Biochem Sci 26:225-229.
27. Prince JA, Blennow K, Gottfries CG, Karlsson I, Oreland L. 1999. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 21: 372-379.
28. Sakai M, Okuda A, Hatayama I, Sato K, Nishi S, Muramatsu M. 1989. Structure and expression of the rat c-jun messenger RNA: tissue distribution and increase during chemical hepatocarcinogenesis. Cancer Res 49:5633-5637.
29. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Muller N. 1999. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 156:1103-1104.
30. Sharp FR, Jasper P, Hall J, Noble L, Sagar SM. 1991. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol 30:801-809.
31. Shevchenko A, Wilm M, Vorm O, Mann M. 1996. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850-858.
32. Sokolov BP, Tcherepanov AA, Haroutunian V, Davis KL. 2000. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biol Psychiatry 48:184-196.
33. Sundman-Eriksson I, Blennow K, Davidsson P, Dandenell AK, Marcusson J. 2002. Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia. Neuropsychobiology 45:7-11.
34. Swerdlow NR, Geyer MA. 1998. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285-301.
35. Tamminga CA, Holcomb HH, Gao XM, Lahti AC. 1995. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 10 Suppl 3:29-37.
36. Terenius L. 2000. Schizophrenia: pathophysiological mechanisms - a synthesis. Brain Res Brain Res Rev 31:401-404.
37. Vermuyten K, Lowenthal A, Karcher D. 1990. Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay. Clin Chim Acta 187:69-78.
38. Whatley SA, Curti D, Marchbanks RM. 1996. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res 21: 995-1004.
39. Whatley SA, Curti D, Das Gupta F, Ferrier IN, Jones S, Taylor C, Marchbanks RM. 1998. Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients. Mol Psychiatry 3:227-237.
40. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL. 1986. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83:7104-7108.
41. Yao JK, Reddy R, van Kammen DP. 2000. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 97:137-151.
42. Yeaman SJ. 1989. The 2-oxo acid dehydrogenase complexes: recent advances. Biochem J 257:625-632.